P1‐006: EXAMINING THE RESILIENCE OF SUPERAGERS: RISK OF CLINICAL PROGRESSION AND Aβ‐ASSOCIATED MEMORY DECLINE OVER 8 YEARS

HOC 83 (45) 3.7 (2.5 5.6) 1.78E-10 t-tau/Ab ratio 130 (70) 3.6 (2.2 6.2) 1.49E-06 AVLT 129 (70) 3.4 (2.0 5.5) 2.06E-06 p-tau/Ab ratio 145 (78) 3.4 (1.9 6.1) 5.59E-05 Ab 139 (75) 3.2 (1.8 5.7) 4.68E-05 p-tau 132 (71) 2.8 (1.7 4.7) 4.81E-05 HC % ICV 109 (59) 2.5 (1.6 3.7) 2.17E-05 t-tau 81 (44) 1.9 (1.3 2.8) 1.25E-03 Risk Factor Combinations N (%) HR (95% CI) p-value HOC, AVLT, & t-tau/Ab ratio Positive 54 (29) 19.5 (5.7 66.7) 2.25E-06 HOC, AVLT, & t-tau/Ab ratio Negative 18 (10) HOC & AVLT HOC & AVLT Positive 64 (35) 13.5 (6.1 30.0) 1.64E-10 HOC positive, AVLT negative 19 (10) 6.2 (2.2 17.2) 4.94E-04 HOC negative, AVLT positive 65 (35) 4.1 (1.9 8.8) 3.82E-04 HOC & AVLT Negative 37 (20) HOC & t-tau/Ab ratio HOC & CSF Positive 65 (35) 10.8 (4.9 23.5) 2.53E-09 HOC Positive, CSF Negative 18 (10) 7.6 (2.4 23.9) 4.75E-04 HOC Negative, CSF Positive 65 (35) 4.5 (2.0 9.9) 1.79E-04 HOC & CSF Negative 37 (20) t-tau/Ap ratio & AVLT CSF & AVLT Positive 100 (54) 7.7 (3.3 18.1) 2.31E-06 CSF Positive, AVLT Negative 30 (16) 2.8 (1.0 7.6) 0.04 CSF Negative, AVLT Positive 29 (16) 2.1 (0.8 5.6) 0.15 CSF & AVLT Negative 26 (14)